Clinical trials: Inflammation Eye Pain
Ocular Inflammation and Pain After Cataract Surgery
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
This is a Phase 2a, 2-part study (designated Parts A and B) that will evaluate APP13007 dose strength and dosing frequency in a randomized double-masked fashion for comparison to the respective matching vehicle placebo.
- Trial name
- NCT04089735
- Testing
- APP13007, 0.05%, APP13007, 0.1%
- Where
- 9 sites in United States
- Volunteers
- 165 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Inflammation, Pain
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery
The objective of this study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT01298752
- Testing
- Mapracorat, Vehicle
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Bausch & Lomb Incorporated
Post Surgical Ocular Inflammation and Pain
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0% ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.
- Trial name
- NCT02793817
- Testing
- KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID
- Where
- 35 sites in United States
- Volunteers
- 520 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Cataract
Nepafenac 0.3% Two Study
The purpose of this study was to assess the safety and efficacy of Nepafenac Ophthalmic Suspension, 0.3% for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
- Trial name
- NCT01318499
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Vehicle 0.3%
- Where
- United States
- Volunteers
- 1,342 people
- Sponsor
- Alcon Research
Cataract
Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification
objective: To evaluate the efficacy of the ophthalmic emulsion PRO-145 in the treatment of inflammation and pain after phacoemulsification.
- Trial name
- PRO-145/III (NCT03693989)
- Testing
- Difluprednate 0.05%, Prednefrin
- Where
- 5 sites in Mexico
- Volunteers
- 178 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Inflammation, Pain
Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate (LE) ophthalmic gel, 0.38% (BID)
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT02208297
- Testing
- Loteprednol Etabonate Gel (BID), Vehicle Gel (BID)
- Where
- United States
- Volunteers
- 326 people
- Sponsor
- Bausch & Lomb Incorporated
Cataract
Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension
A randomized, multicenter, double masked, placebo controlled, parallel group, bioequivalence study to evaluate the clinical equivalence and safety of Nepafenac 0.3% ophthalmic suspension (manufactured by Indoco remedies Ltd.
- Trial name
- NCT03499873
- Testing
- Nepafenac 0.3% Oph Susp, Nepafenac 0.3% Oph Susp (reference)
- Where
- United States
- Volunteers
- 448 people
- Sponsor
- Actavis Inc.
Cataract
A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery
This is a safety and efficacy study of a Dexamethasone Drug Delivery System for anterior segment inflammation and pain following cataract extraction with lens implantation.
- Trial name
- NCT01605942
- Testing
- Dexamethasone Drug Delivery System
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Allergan
Inflammation and Pain Following Ocular Surgery
RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
This study assesses the efficacy and safety of two concentrations of RTA 408 Ophthalmic Suspension in the treatment of patients who have inflammation and pain following ocular surgery.
- Trial name
- NCT02065375
- Testing
- Omaveloxolone Ophthalmic Suspension 1.0%, Omaveloxolone Opthalmic Suspension 0.5%
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- Biogen
Pain, Inflammation
Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
Efficacy study of Bromfenac Ophthalmic Solution in cataract surgery
- Trial name
- NCT00853970
- Testing
- Bromfenac Ophthalmic Solution
- Where
- United States
- Volunteers
- 299 people
- Sponsor
- Bausch & Lomb Incorporated
Cataract, Inflammation
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
The objective of this clinical study is to compare the safety and efficacy of mapracorat ophthalmic suspension, 3% with its vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
- Conditions
- Cataract, Inflammation, Surgery
- Trial name
- NCT01591655
- Testing
- Mapracorat, Vehicle
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Bausch & Lomb Incorporated
Inflammation Eye Pain, Postoperative Cataract
A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.
- Trial name
- OPTIMIZE-1 (NCT05147233)
- Testing
- OCS-01, Vehicle
- Where
- 25 sites in United States
- Volunteers
- 241 people
- Sponsor
- Oculis
Cataract, Pain
LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Loteprednol Etabonate Ophthalmic Gel, (BID and TID) versus Vehicle Group for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.
- Conditions
- Cataract, Pain, Ocular Inflammation
- Trial name
- NCT02786901
- Testing
- Loteprednol Etabonate Ophthalmic Gel dosed TID, Loteprednol Etabonate Ophthalmic Gel dosed BID, Vehicle Gel
- Where
- 6 sites in United States
- Volunteers
- 600 people
- Sponsor
- Bausch & Lomb Incorporated
Ocular Inflammation and Pain
Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery
This Phase 3 study will evaluate APP13007 in comparison to the matching vehicle placebo in a randomized, parallel-group, double-masked fashion.
- Trial name
- NCT04739709
- Testing
- APP13007, 0.05%
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 378 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Pain, Inflammation
Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract
This is a Phase 2, multi-center, randomized, parallel-arm, double-masked, placebo-controlled study. One (1) to 2 days prior to their scheduled cataract surgery, each study subject will be randomized (2:1) in to one of two…
- Trial name
- NCT03496467
- Testing
- Nepafenac PPDS
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Mati Therapeutics Inc.
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and…
- Trial name
- NCT02736175
- Testing
- Dexamethasone
- Volunteers
- 438 people
- Sponsor
- Ocular Therapeutix, Inc.
Cataract
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Cataract surgery is one of the most common surgical procedures performed worldwide. In fact, in 2017, 3.8 million cataracts procedures were performed in the US.
- Trial name
- CLOSE-1 (NCT04246801)
- Testing
- Clobetasol propionate, Vehicle
- Where
- 22 sites in United States
- Volunteers
- 250 people
- Sponsor
- Salvat
Cataract
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Cataract surgery is one of the most common surgical procedures performed worldwide. In fact, in 2017, 3.8 million cataracts procedures were performed in the US.
- Trial name
- CLOSE-2 (NCT04249076)
- Testing
- Clobetasol Propionate, Vehicle
- Where
- 18 sites in United States
- Volunteers
- 215 people
- Sponsor
- Salvat
Keratoconus, Unstable, Collagen Crosslinking
Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study
There is no standard of care medication regimen for the management of pain and inflammation post-corneal crosslinking (CXL), although most cornea specialists agree on use of an antibiotic and steroid eye drop in the immediate…
- Conditions
- Keratoconus, Unstable, Collagen Crosslinking, Postoperative Pain
- Trial name
- NCT04168112
- Testing
- Dextenza, Prednisolone Acetate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sight Medical Doctors PLLC
Inflammation Corneal, Pain, Postoperative
OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the treatment of inflammation and pain following cataract…
- Trial name
- SKYGGN (NCT04130802)
- Testing
- OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL
- Where
- 4 sites in United States
- Volunteers
- 153 people
- Sponsor
- Oculis